Regenicin Appoints Amgen Co-founder Dr. Joseph Rubinfeld to Board of Directors

Rubinfeld expected to assist with FDA approval process for autologous cultured skin substitute, PermaDerm(TM)

27-Aug-2010 - USA

Regenicin, Inc., a clinical-stage biotechnology company, announced that Dr. Joseph Rubinfeld, one of the four original founders of Amgen, Inc., has agreed to join the company's board of directors. Dr. Rubinfeld will be instrumental to assisting the compan's commercialization efforts of PermaDerm(TM), Regenicin's proprietary autologous cultured skin substitute intended to restore the qualities of healthy human skin for use in the treatment of burns, chronic wounds and a variety of plastic surgery procedures.

In addition to his efforts in founding Amgen, Dr. Rubinfeld has a forty-year history in pharmaceutical and consumer product development. His accomplishments include the creation of the multi-billion dollar antibiotic Amoxicillin as well as the first synthetic biodegradable detergent. He has obtained over 100 patents during his distinguished career.

Dr. Rubinfeld began his career as a research scientist with several pharmaceutical and consumer product companies including Schering Plough and Colgate Palmolive. He served for 12 years at Bristol Myers, where in addition to developing Amoxicillin and Chephadroxil, he was instrumental in licensing their original anti-cancer line of products, including Mitomycin, Etoposide, and Bleomycin. After co-founding Amgen in 1980 and serving as its chief of operations, Dr. Rubinfeld has served as an advisor or Board member to a number of companies including AVI BioPharma and Quark Pharmaceuticals. In 1991 he co-founded Supergen, a drug development company based inDublin, California, where he served as President and CEO until 2003 and as a member of the Board of Directors until 2005. During that time he oversaw the company's initial public offering and its rise to a multi-billion dollar market capitalization.

Other news from the department people

Most read news

More news from our other portals

So close that even
molecules turn red...